about
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategiesOvercoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibNew Therapeutic Approaches in Polycythemia VeraEosinophilia in Hematologic DisordersAdvances in the management of myelofibrosisCorrelation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Advanced systemic mastocytosis: from molecular and genetic progress to clinical practiceNovel therapies for myelofibrosisAn unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactionsImatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trNovel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia veraA Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.Lenalidomide therapy in myelofibrosis with myeloid metaplasia.Pomalidomide is active in the treatment of anemia associated with myelofibrosisLenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.JAK2 inhibitors: A reality? A hope?Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsPhase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia.Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy.Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosisEmerging drugs for myelofibrosis.Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge.Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.Practical management of patients with myelofibrosis receiving ruxolitinib.A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet countsEfficacy of ruxolitinib for myelofibrosis.
P50
Q26744113-466A50FE-AC3C-4FC0-B391-0970105332F9Q26750696-2D7FCF4F-6812-41C2-95DA-5E8E487898A6Q26795677-B3920664-0E83-449F-99D3-3E61D14736E3Q26799611-647AFB1E-666E-4550-ADB5-915CD9A22D3BQ27008072-F745F205-9D80-469C-9160-CFBA46538322Q27853179-9238C149-8769-4677-A7FF-A7E4F10F6C82Q28068458-C26C8D14-CCCF-4FE5-A813-A631EC335A82Q28081693-D8C86AE9-8A48-4ACF-B8D8-952021CD61F5Q28264336-7758F268-E0A1-4E16-BFB8-6EB56ADF566CQ30885947-8AD56099-A861-4135-B5ED-32D6C8D2FCA9Q31033077-4E02EC60-395B-4663-8504-A91047086840Q33264010-5DAADCB9-38A1-42D5-8966-F0E29D200AD7Q33360707-F383735F-797B-44E2-A3E4-0925B7E71CA5Q33366045-BDE589AE-A2AD-4BB1-B651-EAB7C1287F1FQ33366921-26366C82-B3E3-467F-8F3B-F18444204772Q33370821-72097CA9-A3BA-45AC-97BA-0689DC7D9A66Q33385644-8DBA97D1-3C65-4AAA-AFCA-B776A0441369Q33386057-56D09B5B-C09E-4CBD-9B28-217EB75EBC9DQ33386368-FD5A80A7-A90D-4E91-832E-37504EE25C55Q33386506-B365D0B8-D369-4458-9F4A-53B122B33812Q33387514-E90518EC-11C5-406E-A7FD-7755C5EF21EAQ33389328-4FB97455-6E4B-4CB5-A65D-D453458CD923Q33391401-AC346631-6991-47FF-9AEC-33A48C8BFF43Q33391404-AEB28260-12B9-497B-ADD7-5865B13C7709Q33391880-2F16772C-B017-42B3-8730-7A198BA1C247Q33392185-E84E74C2-11EA-4823-A9D0-7DDBCAF43390Q33397219-A0E60870-41DA-4D61-B7A2-55F0744E3DC8Q33399980-A3CD2F06-0292-4499-B26F-011B8B9067A0Q33400570-752BC053-6B6D-49D7-89E6-13D269DD968FQ33404574-38CCD80F-DE14-4AF8-B839-264D330E4B21Q33405766-85CBE85E-A590-47F4-806A-85E84EC81AC4Q33405985-3D4F1F8D-CF8C-4A70-BDDD-B17D23C3DED2Q33406990-F49F3F11-D655-4251-8362-F3CE372EA827Q33407572-1B8364A3-CD3D-414C-A868-6D7869F2F5DFQ33408634-CC436CBE-76C8-4CE7-8FBC-470F735B18E9Q33410346-1434D52E-47FD-4A98-9DD2-62A089E9DA1DQ33410649-06E135BA-1F30-4C83-8CA9-42F2D7A69404Q33411637-1D4B2660-AE59-4421-A8C3-30BEA1B3336BQ33411755-0840102C-0975-4C99-A09F-8D82A6F7A928Q33415489-1C70B458-D9A4-44FF-8471-F5E7257273BF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Srdan Verstovsek
@ast
Srdan Verstovsek
@en
Srdan Verstovsek
@es
Srdan Verstovsek
@nl
type
label
Srdan Verstovsek
@ast
Srdan Verstovsek
@en
Srdan Verstovsek
@es
Srdan Verstovsek
@nl
altLabel
S Verstovsek
@en
S. Verstovsek
@en
Verstovsek S
@en
Verstovsek S.
@en
Verstovsek
@en
prefLabel
Srdan Verstovsek
@ast
Srdan Verstovsek
@en
Srdan Verstovsek
@es
Srdan Verstovsek
@nl
P214
P106
P214
P31
P496
0000-0002-6912-8569
P7859
lccn-nb2010030874